Pyxis Oncology, Inc. (PYXS)Healthcare | Biotechnology | Boston, United States | NasdaqGS
2.32 USD
+0.03
(1.094%)
⇧
(July 15, 2026, 9:55 a.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 4:42 a.m. EDT
The investment case here is severely compromised by a catastrophic multi-year decline. Despite a recent bounce in share price, the underlying business has lost nearly 60% of its value over the last three years, with the most recent annual performance showing a staggering -61% drop. This is not a temporary correction; it is a structural deterioration where the market has priced out the company's prospects entirely. The balance sheet is fragile, burning through cash with negative free cash flow and no revenue growth to speak of. While analysts offer a 'strong buy' rating based on potential catalysts, the data shows a company in freefall. Furthermore, the options market confirms this pessimism, with traders aggressively buying deep out-of-the-money puts while avoiding calls, signaling a fear of further collapse rather than a belief in a recovery. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.261809 |
| AutoARIMA | 0.307167 |
| MSTL | 0.461164 |
| AutoETS | 0.462113 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.11 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.144 |
| Excess Kurtosis | -1.27 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 58.389 |
| Revenue per Share | 0.221 |
| Market Cap | 146,667,936 |
| Forward P/E | -1.92 |
| Beta | 1.31 |
| Website | https://www.pyxisoncology.com |
As of July 11, 2026, 4:42 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in out-of-the-money puts (3.2k contracts at the $5.00 strike) compared to negligible call volume at that level. While there is some call activity at the $5.00 strike, the overwhelming weight of capital is in put options, suggesting a bearish view on the near-to-intermediate term.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9243697 |
| Address1 | 321 Harrison Avenue |
| Address2 | 11th Floor, Suite 1 |
| All Time High | 19.0 |
| All Time Low | 0.833 |
| Ask | 2.94 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,719,280 |
| Average Daily Volume3 Month | 863,554 |
| Average Volume | 863,554 |
| Average Volume10Days | 1,719,280 |
| Beta | 1.306 |
| Bid | 1.65 |
| Bid Size | 2 |
| Book Value | 0.498 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.315 |
| Current Ratio | 2.757 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 2.3252 |
| Day Low | 2.27 |
| Debt To Equity | 58.389 |
| Display Name | Pyxis Oncology |
| Earnings Timestamp | 1,778,761,800 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -78,757,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.553 |
| Enterprise To Revenue | 8.827 |
| Enterprise Value | 122,323,056 |
| Eps Current Year | -1.22375 |
| Eps Forward | -1.205 |
| Eps Trailing Twelve Months | -1.3 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.149 |
| Fifty Day Average Change | 0.16600013 |
| Fifty Day Average Change Percent | 0.077245295 |
| Fifty Two Week Change Percent | 92.436966 |
| Fifty Two Week High | 5.55 |
| Fifty Two Week High Change | -3.2350001 |
| Fifty Two Week High Change Percent | -0.5828829 |
| Fifty Two Week Low | 0.97 |
| Fifty Two Week Low Change | 1.345 |
| Fifty Two Week Low Change Percent | 1.3865979 |
| Fifty Two Week Range | 0.97 - 5.55 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,633,699,800,000 |
| Float Shares | 29,411,515 |
| Forward Eps | -1.205 |
| Forward P E | -1.9211618 |
| Free Cashflow | -34,457,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 56 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.82768 |
| Gross Profits | 11,470,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13598 |
| Held Percent Institutions | 0.42442 |
| Implied Shares Outstanding | 63,355,482 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-10-08 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has an in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts. |
| Long Name | Pyxis Oncology, Inc. |
| Market | us_market |
| Market Cap | 146,667,936 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_629268721 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -81,735,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 145,400,831 |
| Number Of Analyst Opinions | 8 |
| Open | 2.3 |
| Operating Cashflow | -66,967,000 |
| Operating Margins | -6.0019503 |
| Payout Ratio | 0.0 |
| Phone | 617 453 3596 |
| Previous Close | 2.29 |
| Price Eps Current Year | -1.8917263 |
| Price Hint | 4 |
| Price To Book | 4.6485944 |
| Price To Sales Trailing12 Months | 10.58363 |
| Profit Margins | 0.0 |
| Quick Ratio | 2.481 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.025000095 |
| Regular Market Change Percent | 1.0940962 |
| Regular Market Day High | 2.3252 |
| Regular Market Day Low | 2.27 |
| Regular Market Day Range | 2.27 - 2.3252 |
| Regular Market Open | 2.3 |
| Regular Market Previous Close | 2.29 |
| Regular Market Price | 2.315 |
| Regular Market Time | 1,784,123,759 |
| Regular Market Volume | 25,552 |
| Return On Assets | -0.51941 |
| Return On Equity | -1.21656 |
| Revenue Per Share | 0.221 |
| Sand P52 Week Change | 0.2043345 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 63,355,482 |
| Shares Percent Shares Out | 0.0361 |
| Shares Short | 2,289,798 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 1,741,743 |
| Short Name | Pyxis Oncology, Inc. |
| Short Percent Of Float | 0.048899997 |
| Short Ratio | 2.04 |
| Source Interval | 15 |
| State | MA |
| Symbol | PYXS |
| Target High Price | 8.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 6.75 |
| Target Median Price | 7.0 |
| Total Cash | 41,018,000 |
| Total Cash Per Share | 0.647 |
| Total Debt | 18,257,000 |
| Total Revenue | 13,858,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.3 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.342925 |
| Two Hundred Day Average Change | -0.027925014 |
| Two Hundred Day Average Change Percent | -0.011918868 |
| Type Disp | Equity |
| Volume | 25,552 |
| Website | https://www.pyxisoncology.com |
| Zip | 2,118 |